Zobrazeno 1 - 10
of 192
pro vyhledávání: ''
Autor:
Guofan Xu, Lei Feng, Hun Ju Lee, Michelle Avellaneda, Preetesh Jain, Linghua Wang, Luis Fayad, Omar Moghrabi, L. Jeffrey Medeiros, Cezar Iliescu, Nathan Fowler, Shuangtao Zhao, Yang Liu, Selvi Thirumurthi, Michael L. Wang, Chi Young Ok, Maria Badillo, Lucy Navsaria, Graciela M. Nogueras González, David Santos, Christopher R. Flowers, Francisco Vega, Guilin Tang, Holly Hill, Rashmi Kanagal-Shamanna, Fredrick B. Hagemeister, Yixin Yao
Publikováno v:
J Clin Oncol
PURPOSE Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 y
Autor:
Fritz Offner, Karima Amaador, Kazem Nasserinejad, Dries Deeren, Efstathios Kastritis, Steven T. Pals, Willem Kraan, Jeanette K. Doorduijn, Roberto D Liu, Monique C. Minnema, Marcel Kap, Marie José Kersten, Lara H Böhmer, Lidwine W. Tick, Meletios A. Dimopoulos, Josephine M.I. Vos, Martine E D Chamuleau, Maria Gavriatopoulou
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
PURPOSE Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor
Autor:
Douglas S. Lee, Anca Prica, Peter C. Austin, Andrea Pang, Paaladinesh Thavendiranathan, Husam Abdel-Qadir, Darryl P. Leong, Oscar Calvillo-Argüelles, Nasruddin Sabrie, Kumaraswamy Nanthakumar
Publikováno v:
Journal of Clinical Oncology. 39:3453-3462
PURPOSE Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL). It increases the risk of atrial fibrillation (AF) and bleeding and there are concerns about heart failure (HF) and central nervous system ischemic events. The magnitude of the
Autor:
L. Claire Tsao, Adrian Wiestner, Lei Zhang, David Ipe, Sarah E. M. Herman, Maher Albitar, Susan Soto, Xin Tian, James P. Dean, Mei Cheng, Wanlong Ma, Erika M Gaglione, Inhye E. Ahn
Publikováno v:
Journal of Clinical Oncology. 39:576-585
PURPOSE Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for pr
Autor:
Rosa Nadal, Piyush K. Agarwal, Sumanta K. Pal, Biren Saraiya, Howard L. Parnes, Donald P. Bottaro, Daniel Girardi, Vladimir Valera, Mohammad Hadi Bagheri, Lisa Ley, Scot Anthony Niglio, Olena Sierra Ortiz, Seth M. Steinberg, Yangmin M. Ning, Primo N. Lara, William D. Figg, Paul Monk, Heather J. Chalfin, Mark N. Stein, Howard Streicher, Carlos Diaz, Marissa Mallek, Amir Mortazavi, Maria J. Merino, Jacqueline Cadena, Rene Costello, Min-Jung Lee, Jane B. Trepel, William L. Dahut, Nicole N. Davarpanah, James L. Gulley, Andrea B. Apolo, John J. Wright, Jennifer Jones, Lisa M. Cordes
Publikováno v:
Journal of Clinical Oncology
PURPOSE We assessed the safety and efficacy of cabozantinib and nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances. PATIENTS AND METHODS Pati
Autor:
Jessica M. Salmon, Andrew W. Roberts, Stefan K. Bohlander, Sarah MacRaild, Ing Soo Tiong, John V. Reynolds, Andrew H. Wei, Shaun Fleming, Adam Ivey, Stephen B. Ting, Chong Chyn Chua, Chun Yew Fong, Ian J. Majewski, Sun Loo, Fiona C. Brown
Publikováno v:
Journal of Clinical Oncology. 38:3506-3517
PURPOSE The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. The tolerability and e
Autor:
Yu Deng, Mark A. Socinski, Hina Patel, Geetha Shankar, Denis Moro-Sibilot, Martin Früh, Shelley Coleman, Wei Yu, Elisabeth Piault, Martin Reck, Mikhail Shtivelband, T. Wehler, José Luis González Larriba, Carlo Barone, Anthony Lee, Naoyuki Nogami, Jeffrey Rothenstein, Francisco Orlandi, Claudia Kelsch
Publikováno v:
Journal of Clinical Oncology
PURPOSE Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non–small-cell lung cancer (NSCLC). We present safety and p
Autor:
Richard F. Schlenk, Gesine Bug, Decider Study Team, Arnold Ganser, Wolfram Brugger, Helmut R. Salih, Claudia Schmoor, Hans-Walter Lindemann, Ralph Wäsch, Michael Lübbert, Konstanze Döhner, Olga Grishina, Carsten Schwaenen, Michael Heuser, Andreas Neubauer, Katharina Götze, Ulrich Germing, Marcus M Schittenhelm, Justus Duyster, Gerhard Heil, Andrea Kuendgen, Aristoteles Giagounidis, Martina Crysandt, Hartmut Döhner, Björn Hackanson, Felicitas Thol, Edgar Jost, Jürgen Krauter, Maike de Wit, Annette M. May, Sebastian Scholl, Heiko Becker, Carsten Müller-Tidow
Publikováno v:
Journal of Clinical Oncology. 38:257-270
PURPOSE DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with a 2 × 2 factorial
Autor:
Sarmad Sadeghi, Laurence A. Doyle, Edward M. Newman, Primo N. Lara, Rahul R. Parikh, Christopher J. Hoimes, David I. Quinn, Susan Groshen, Denice D. Tsao-Wei, Tanya B. Dorff, Amir Mortazavi, Cheryl Kefauver
Publikováno v:
Journal of Clinical Oncology. 37:2682-2688
PURPOSE Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Cancer Therapy Evaluation Program–sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribuli
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W